LEXICON PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-12.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2020-03-12
- LEXICON PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2019 was $0.00.
- LEXICON PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2018 was $0.00.
- LEXICON PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2017 was -$5.32M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month |
|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-03-12 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-12 |
| 2017-12-31 | -$5.32M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |